Australia's CSL rises on launching trials for patented manufacturing process

CSL

29/07/2026 01:54

** Shares of biotechnology major CSL CSL.AX rise 5.6% to A$126.59, their highest since July 9
** Stock on track for best day since June 19, if gains hold
** Co says it will undertake clinical trials to support the regulatory approval process of Horizon 2, a patented manufacturing process 
** Horizon 2 is designed to boost immunoglobulin production from the same amount of plasma
** Stock down 26.9% YTD 

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)
 ((Jasmeenaraislam.Shaikh@thomsonreuters.com;))